ID
39965
Beschrijving
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration
Trefwoorden
Versies (1)
- 06/03/2020 06/03/2020 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
6 de março de 2020
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055
Week 8; 12; 16; 20; 32; 36; 40; 44; 48 - ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; Ocular Status; External Ocular Exam; Eye Lid and Lash Exam
Similar models
Week 8; 12; 16; 20; 32; 36; 40; 44; 48 - ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; Ocular Status; External Ocular Exam; Eye Lid and Lash Exam
C2985720 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
C1264639 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
C2646699 (UMLS CUI [1,3])
C0229089 (UMLS CUI [1,2])
C0444686 (UMLS CUI [1,3])